Vai al contenuto principale della pagina

Multimodality Treatments in Metastatic Gastric Cancer



(Visualizza in formato marc)    (Visualizza in BIBFRAME)

Autore: Petrillo Angelica Visualizza persona
Titolo: Multimodality Treatments in Metastatic Gastric Cancer Visualizza cluster
Pubblicazione: Basel, Switzerland, : MDPI - Multidisciplinary Digital Publishing Institute, 2021
Descrizione fisica: 1 electronic resource (162 p.)
Soggetto topico: Medicine
Soggetto non controllato: advanced gastric cancer
precision medicine
new drug development
gastro-oesophageal cancer
mutational concordance
exome sequencing
formalin fixed paraffin embedded
biomarkers
gastric cancer
metastatic
body composition
sarcopenia
visceral fat area
subcutaneous fat area
outcome
toxicity
liver metastasis
conversion surgery
hepatectomy
stage iv gastric cancer
immune checkpoint inhibitors
Epstein Barr Virus
tumor mutational burden
microsatellite instability
predictive biomarkers
CAR T cell therapy
vaccines
nutritional status
metastatic gastric cancer
target therapy
bone flare
stage IV
treatment
RANK-L
liquid biopsy
circulating tumor cell
cfDNA
ctDNA
epithelial-mesenchymal transition
resistance to treatment
HER2-inhibition
VEGFR-inhibition
immunotherapy
response monitoring
Persona (resp. second.): PetrilloAngelica
Sommario/riassunto: Gastric cancer represents one of the most frequent and lethal tumors worldwide today, finding itself in the fifth place in incidence and the third in mortality. Surgery remains the only curative treatment for localized tumors, but only 20% of patients are suitable for surgery due to the lack of specific symptoms and the late diagnosis, especially in Western countries. Additionally, even in patients who receive curative treatment, rates of locoregional relapse and distant metastasis remain high. Palliative chemotherapy is the principal treatment in cases of metastatic disease even if the prognosis of patients receiving chemotherapy is still poor. Therefore, a multidisciplinary evaluation is important in order to improve the efficacy of active treatments. In this context, there is an unmet need for a better understanding of genetic alterations and prognostic and predictive factors in order to choose the best tailored therapy for each patient. The aim of this Special Issue is to focus on the results and problems of multimodality treatment in metastatic gastric cancer, the search for prognostic and predictive factors, and the evaluation of novel strategies for individualized treatment. We are inviting relevant original research, systematic reviews, meta-analyses, and short communications covering the above-mentioned topics.
Titolo autorizzato: Multimodality Treatments in Metastatic Gastric Cancer  Visualizza cluster
Formato: Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione: Inglese
Record Nr.: 9910557390503321
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui